PNC Financial Services Group’s ARS Pharmaceuticals SPRY Stock Holding History

PNC Financial Services Group’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.14K	Buy	1,016 +984	+3,075%	+$8.46K	﹤0.01%	4188
2026 Q1	$257	Sell	32 -4	-11%	-$38	﹤0.01%	5007
2025 Q4	$419	Buy	+36	New	+$350	﹤0.01%	4879
2025 Q3	–	Sell	-3,935	Closed	-$68.7K	–	5226
2025 Q2	$68.7K	Buy	3,935 +25	+0.6%	+$361	﹤0.01%	2935
2025 Q1	$49.2K	Buy	3,910 +3,905	+78,100%	+$47K	﹤0.01%	3102
2024 Q4	$53	Buy	+5	New	+$70	﹤0.01%	4734
2024 Q2	–	Sell	-8	Closed	-$82	–	4910
2024 Q1	$82	Hold	8	–	–	﹤0.01%	4649
2023 Q4	$44	Buy	+8	New	+$35	﹤0.01%	4574

Other funds holding SPRY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

PCML

Pavaki Capital Management LLC Pueblo, Colorado $287M AUM

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

PNC Financial Services Group's SPRY Position: Q2 2026 in Review

PNC Financial Services Group increased its ARS Pharmaceuticals (SPRY) stake by 3,075% in Q2 2026, buying an estimated $8.46K and bringing the position to 1,016 shares worth $8.14K. The position accounts for ﹤0.01% of the portfolio, ranked #4188.

PNC Financial Services Group first reported a position in SPRY in Q4 2023 and has held it in 8 quarters since. The position peaked at $68.7K in Q2 2025. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

PNC Financial Services Group held 1,016 shares of ARS Pharmaceuticals worth $8.14K as of Q2 2026.
PNC Financial Services Group bought 984 ARS Pharmaceuticals shares in Q2 2026, an estimated $8.46K.
ARS Pharmaceuticals made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #4188 holding.
PNC Financial Services Group first reported a position in ARS Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
PNC Financial Services Group's ARS Pharmaceuticals position peaked at $68.7K in Q2 2025.
68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.